Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children
- PMID: 21846636
- PMCID: PMC3156924
- DOI: 10.1093/infdis/jir436
Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children
Abstract
Background: Two doses of either trivalent live attenuated or inactivated influenza vaccines (LAIV and TIV, respectively) are approved for young children (≥ 24 months old for LAIV and ≥ 6 months old for TIV) and induce protective antibody responses. However, whether combinations of LAIV and TIV are safe and equally immunogenic is unknown. Furthermore, LAIV is more protective than TIV in children for unclear reasons.
Methods: Children 6-35 months old were administered, 1 month apart, 2 doses of either TIV or LAIV, or combinations of LAIV and TIV in both prime/boost sequences. Influenza-specific antibodies were measured by hemagglutination inhibition (HAI), and T cells were studied in flow cytometric and functional assays. Highly conserved M1, M2, and NP peptides predicted to be presented by common HLA class I and II were used to stimulate interferon-γ enzyme-linked immunospot responses.
Results: All LAIV and/or TIV combinations were well tolerated and induced similar HAI responses. In contrast, only regimens containing LAIV induced influenza-specific CD4(+), CD8(+), and γδ T cells, including T cells specific for highly conserved influenza peptides.
Conclusions: Prime/boost combinations of LAIV and TIV in young children were safe and induced similar protective antibodies. Only LAIV induced CD4(+), CD8(+), and γδ T cells relevant for broadly protective heterosubtypic immunity.
Clinical trials registration: NCT00231907.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3156924/bin/infdisjir436f01_3c.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3156924/bin/infdisjir436f02_3c.gif)
![Figure 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3156924/bin/infdisjir436f03_ht.gif)
Similar articles
-
Inactivated influenza virus vaccines: the future of TIV and QIV.Curr Opin Virol. 2017 Apr;23:102-106. doi: 10.1016/j.coviro.2017.04.005. Epub 2017 May 12. Curr Opin Virol. 2017. PMID: 28505524 Free PMC article. Review.
-
Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.J Infect Dis. 2014 Jul 15;210(2):224-33. doi: 10.1093/infdis/jiu079. Epub 2014 Feb 4. J Infect Dis. 2014. PMID: 24495909 Free PMC article.
-
Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.J Infect Dis. 2011 Nov 15;204(10):1475-82. doi: 10.1093/infdis/jir561. Epub 2011 Sep 23. J Infect Dis. 2011. PMID: 21949042 Clinical Trial.
-
The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults.Influenza Other Respir Viruses. 2011 Mar;5(2):67-75. doi: 10.1111/j.1750-2659.2010.00183.x. Epub 2010 Nov 19. Influenza Other Respir Viruses. 2011. PMID: 21306569 Free PMC article. Review.
-
Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.J Virol. 2006 Dec;80(23):11756-66. doi: 10.1128/JVI.01460-06. Epub 2006 Sep 13. J Virol. 2006. PMID: 16971435 Free PMC article.
Cited by
-
An IFNγ-dependent immune-endocrine circuit lowers blood glucose to potentiate the innate antiviral immune response.Nat Immunol. 2024 Jun;25(6):981-993. doi: 10.1038/s41590-024-01848-3. Epub 2024 May 29. Nat Immunol. 2024. PMID: 38811816
-
Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections.Vaccines (Basel). 2024 Apr 29;12(5):478. doi: 10.3390/vaccines12050478. Vaccines (Basel). 2024. PMID: 38793729 Free PMC article. Review.
-
Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.Nat Commun. 2023 Dec 5;14(1):8053. doi: 10.1038/s41467-023-43842-7. Nat Commun. 2023. PMID: 38052824 Free PMC article.
-
Both Humoral and Cellular Immunity Limit the Ability of Live Attenuated Influenza Vaccines to Promote T Cell Responses.J Immunol. 2024 Jan 1;212(1):107-116. doi: 10.4049/jimmunol.2300343. J Immunol. 2024. PMID: 37982700
-
Identification and In Silico Characterization of a Conserved Peptide on Influenza Hemagglutinin Protein: A New Potential Antigen for Universal Influenza Vaccine Development.Nanomaterials (Basel). 2023 Oct 20;13(20):2796. doi: 10.3390/nano13202796. Nanomaterials (Basel). 2023. PMID: 37887946 Free PMC article.
References
-
- Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59:1–62. - PubMed
-
- Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. New Engl J Med. 2007;356:685–96. - PubMed
-
- Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J. 2004;23:189–97. - PubMed
-
- Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168–75. - PubMed
-
- Swierkosz EM, Newman FK, Anderson EL, Nugent SL, Mills GB, Belshe RB. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis. 1994;169:1121–4. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous